JP2013523096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523096A5 JP2013523096A5 JP2013501542A JP2013501542A JP2013523096A5 JP 2013523096 A5 JP2013523096 A5 JP 2013523096A5 JP 2013501542 A JP2013501542 A JP 2013501542A JP 2013501542 A JP2013501542 A JP 2013501542A JP 2013523096 A5 JP2013523096 A5 JP 2013523096A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polynucleotide
- composition
- vector
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 127
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 108
- 108091033319 polynucleotide Proteins 0.000 claims description 103
- 239000002157 polynucleotide Substances 0.000 claims description 103
- 102000040430 polynucleotide Human genes 0.000 claims description 103
- 239000013598 vector Substances 0.000 claims description 87
- 239000000203 mixture Substances 0.000 claims description 85
- 229920001184 polypeptide Polymers 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 70
- 241000712461 unidentified influenza virus Species 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 230000009385 viral infection Effects 0.000 claims description 32
- 101710154606 Hemagglutinin Proteins 0.000 claims description 26
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 26
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 26
- 101710176177 Protein A56 Proteins 0.000 claims description 26
- 239000000185 hemagglutinin Substances 0.000 claims description 26
- 102000011931 Nucleoproteins Human genes 0.000 claims description 24
- 108010061100 Nucleoproteins Proteins 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 230000028993 immune response Effects 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 20
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 18
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 18
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 14
- 108091026890 Coding region Proteins 0.000 claims description 12
- 102000005348 Neuraminidase Human genes 0.000 claims description 12
- 108010006232 Neuraminidase Proteins 0.000 claims description 12
- 241000272525 Anas platyrhynchos Species 0.000 claims description 10
- 206010022000 influenza Diseases 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 241000271566 Aves Species 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 238000002649 immunization Methods 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims description 8
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 230000002207 retinal effect Effects 0.000 claims description 6
- 108010041986 DNA Vaccines Proteins 0.000 claims description 4
- 229940021995 DNA vaccine Drugs 0.000 claims description 4
- 108010070675 Glutathione transferase Proteins 0.000 claims description 4
- 102000005720 Glutathione transferase Human genes 0.000 claims description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 4
- 241000712431 Influenza A virus Species 0.000 claims description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 4
- 108700026244 Open Reading Frames Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102000002933 Thioredoxin Human genes 0.000 claims description 4
- 108010022394 Threonine synthase Proteins 0.000 claims description 4
- 241000700618 Vaccinia virus Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 230000005875 antibody response Effects 0.000 claims description 4
- 102000028861 calmodulin binding Human genes 0.000 claims description 4
- 108091000084 calmodulin binding Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 4
- 239000005090 green fluorescent protein Substances 0.000 claims description 4
- 230000028996 humoral immune response Effects 0.000 claims description 4
- 229960003971 influenza vaccine Drugs 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 108060008226 thioredoxin Proteins 0.000 claims description 4
- 229940094937 thioredoxin Drugs 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000037452 priming Effects 0.000 claims description 3
- 238000002255 vaccination Methods 0.000 claims description 3
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 claims description 2
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 claims description 2
- 108050001427 Avidin/streptavidin Proteins 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- 241000272829 Cairina Species 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 241001195348 Nusa Species 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 241000288906 Primates Species 0.000 claims description 2
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 claims description 2
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims description 2
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 102000044159 Ubiquitin Human genes 0.000 claims description 2
- 108090000848 Ubiquitin Proteins 0.000 claims description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 101150042295 arfA gene Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- -1 cationic lipid Chemical class 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 108010090623 galactose binding protein Proteins 0.000 claims description 2
- 102000021529 galactose binding proteins Human genes 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 101150066555 lacZ gene Proteins 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000016379 mucosal immune response Effects 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 101150087557 omcB gene Proteins 0.000 claims description 2
- 101150115693 ompA gene Proteins 0.000 claims description 2
- 101150093139 ompT gene Proteins 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 101150040383 pel2 gene Proteins 0.000 claims description 2
- 101150050446 pelB gene Proteins 0.000 claims description 2
- 239000002574 poison Substances 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- 108010077051 polycysteine Proteins 0.000 claims description 2
- 108010039177 polyphenylalanine Proteins 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 101150044170 trpE gene Proteins 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000002435 venom Substances 0.000 claims description 2
- 231100000611 venom Toxicity 0.000 claims description 2
- 210000001048 venom Anatomy 0.000 claims description 2
- 241001500351 Influenzavirus A Species 0.000 claims 1
- 229920000805 Polyaspartic acid Polymers 0.000 claims 1
- 235000002597 Solanum melongena Nutrition 0.000 claims 1
- 244000061458 Solanum melongena Species 0.000 claims 1
- 108010064470 polyaspartate Proteins 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31823210P | 2010-03-26 | 2010-03-26 | |
| US61/318,232 | 2010-03-26 | ||
| PCT/US2011/030205 WO2011120045A1 (en) | 2010-03-26 | 2011-03-28 | Ectodomains of influenza matrix 2 protein, expression system, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523096A JP2013523096A (ja) | 2013-06-17 |
| JP2013523096A5 true JP2013523096A5 (enExample) | 2013-07-25 |
Family
ID=44673677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501542A Pending JP2013523096A (ja) | 2010-03-26 | 2011-03-28 | インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20130115234A1 (enExample) |
| EP (1) | EP2552490A4 (enExample) |
| JP (1) | JP2013523096A (enExample) |
| CN (1) | CN103118709A (enExample) |
| AU (1) | AU2011230491A1 (enExample) |
| CA (1) | CA2793772A1 (enExample) |
| SG (1) | SG184155A1 (enExample) |
| WO (1) | WO2011120045A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
| US10286062B2 (en) | 2013-07-09 | 2019-05-14 | Texas Tech University System | Universal influenza vaccine |
| CN105018441A (zh) * | 2014-04-22 | 2015-11-04 | 中国科学院生物物理研究所 | 流感病毒rna聚合酶结晶的方法 |
| CN105002149B (zh) * | 2014-04-22 | 2018-04-06 | 中国科学院生物物理研究所 | 流感病毒rna聚合酶纯化或结晶的方法 |
| WO2016131945A1 (en) * | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| WO2016176761A1 (en) * | 2015-05-01 | 2016-11-10 | Immunovaccine Technologies Inc., | Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines |
| CN110290805A (zh) * | 2017-01-03 | 2019-09-27 | 埃默杰克斯疫苗控股有限公司 | 通用流感疫苗组合物 |
| CN108373507A (zh) * | 2018-01-18 | 2018-08-07 | 复旦大学 | 一种重组亚单位禽流感疫苗Sef4M2e |
| CN120435313A (zh) * | 2022-11-29 | 2025-08-05 | 斯克里普斯研究学院 | 包含新的纳米粒支架的疫苗 |
| AU2024240459A1 (en) * | 2023-03-17 | 2025-10-09 | Versatope Therapeutics, Inc. | Membrane vesicles comprising multiple influenza antigens for vaccines |
| CN118530314B (zh) * | 2024-06-06 | 2025-09-30 | 中国科学院武汉病毒研究所 | 广谱型流感疫苗抗原片段、重组益生菌及应用 |
| CN119350508A (zh) * | 2024-10-22 | 2025-01-24 | 成都纳微金生物技术有限公司 | 带广谱表位的三价流感纳米颗粒疫苗及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| US7361352B2 (en) * | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| KR101138067B1 (ko) * | 2002-05-16 | 2012-04-24 | 버베리안 노딕 에이/에스 | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스 |
| US7354589B2 (en) * | 2003-01-16 | 2008-04-08 | The Wistar Institute | Multiple antigenic agents and methods for using the same |
| CN1280310C (zh) * | 2004-09-29 | 2006-10-18 | 清华大学 | 具有防治流感作用的融合蛋白及其编码基因与应用 |
| US8124091B2 (en) * | 2004-12-06 | 2012-02-28 | Kyowa Hakko Kirin Co., Ltd. | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
| US20090162400A1 (en) * | 2004-12-21 | 2009-06-25 | Powell Thomas J | Compositions of influenza viral proteins and methods of use thereof |
| JP2008524261A (ja) * | 2004-12-21 | 2008-07-10 | バクシネート コーポレーション | インフルエンザウイルスタンパク質の組成物およびその使用方法 |
| US20070160628A1 (en) * | 2005-08-31 | 2007-07-12 | Birkett Ashley J | Stabilized virus-like particles and epitope display systems |
| EP1925318A1 (en) * | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
| EP1985305A1 (en) * | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| US20090196915A1 (en) * | 2007-08-21 | 2009-08-06 | Gary Van Nest | Composition and methods of making and using influenza proteins |
| CA2976814C (en) * | 2007-08-27 | 2022-12-13 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods for treating influenza |
| CN101531719B (zh) * | 2008-06-06 | 2011-09-14 | 江苏省农业科学院 | 一种禽流感基因工程多肽抗原 |
| CN101643721B (zh) * | 2009-08-17 | 2011-05-25 | 诺华生物科技（武汉）有限责任公司 | 广谱安全型动物用抗甲型流感病毒疫苗 |
-
2011
- 2011-03-28 AU AU2011230491A patent/AU2011230491A1/en not_active Abandoned
- 2011-03-28 WO PCT/US2011/030205 patent/WO2011120045A1/en not_active Ceased
- 2011-03-28 EP EP11760377.9A patent/EP2552490A4/en not_active Withdrawn
- 2011-03-28 US US13/637,305 patent/US20130115234A1/en not_active Abandoned
- 2011-03-28 SG SG2012069555A patent/SG184155A1/en unknown
- 2011-03-28 CA CA2793772A patent/CA2793772A1/en not_active Abandoned
- 2011-03-28 JP JP2013501542A patent/JP2013523096A/ja active Pending
- 2011-03-28 CN CN2011800257513A patent/CN103118709A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523096A5 (enExample) | ||
| EP2772267B1 (en) | Immunogenic compositions and methods | |
| JP5654345B2 (ja) | 多量体マルチエピトープインフルエンザワクチン | |
| Chroboczek et al. | Virus-like particles as vaccine. | |
| Stachyra et al. | DNA vaccines against influenza. | |
| EP1968632B1 (en) | Improved influenza vaccine | |
| JP2013523096A (ja) | インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用 | |
| KR20220082042A (ko) | 인플루엔자 바이러스 백신 및 이의 용도 | |
| KR20240019213A (ko) | 코로나바이러스를 위한 바이러스 유사 입자 백신 | |
| AU2011360572B2 (en) | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines | |
| WO2023154821A2 (en) | Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity | |
| US20260007734A1 (en) | Immunogenic compositions for the prevention of influenza a | |
| WO2025260634A1 (zh) | Rsv和hmpv融合f蛋白及其用途 | |
| WO2025260633A1 (zh) | Rsv和hmpv融合f蛋白及其用途 | |
| HK1192455A (en) | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |